Nektar Therapeutics (NKTR) Expected to Announce Earnings on Thursday

Key Points

• Nektar Therapeutics (NKTR) is scheduled to announce its Q2 2025 earnings on August 7th, with expected earnings of ($2.58) per share and revenue of $9.42 million.
($3.30) per share, missing estimates, alongside a significant negative return on equity of -329.54%.
• Analysts have recently increased their price targets for Nektar Therapeutics, with some raising targets to as high as $120.00, reflecting a generally positive outlook despite recent setbacks.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect Nektar Therapeutics to post earnings of ($2.58) per share and revenue of $9.42 million for the quarter.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same period last year, the company earned ($2.70) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Down 1.4%

NASDAQ:NKTR traded down $0.33 during trading hours on Tuesday, reaching $22.95. 102,171 shares of the company's stock were exchanged, compared to its average volume of 861,753. The firm has a market capitalization of $284.75 million, a price-to-earnings ratio of -2.39 and a beta of 0.95. Nektar Therapeutics has a 1-year low of $6.45 and a 1-year high of $37.38. The company has a 50-day moving average of $18.71 and a 200 day moving average of $13.90.

Institutional Trading of Nektar Therapeutics

A number of large investors have recently bought and sold shares of NKTR. AQR Capital Management LLC boosted its holdings in Nektar Therapeutics by 336.9% during the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 2,807,595 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Nektar Therapeutics during the 1st quarter valued at $68,000. Finally, Rhumbline Advisers raised its position in Nektar Therapeutics by 23.3% during the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on NKTR shares. BTIG Research increased their price objective on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. HC Wainwright raised their price objective on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. B. Riley lifted their price target on Nektar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research report on Monday, May 12th. Finally, Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $88.33.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.